BEIJING, July 24, 2025 /PRNewswire/ -- Life has never been happier for Xu Furong.
The 86-year-old resident of Nanliuzhuang village starts each morning with a bit of...
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators
NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO)...
DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...
Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection
New findings highlight the central role of...
Company responds to heartfelt outreach with a gift of hope and stability
PHILADELPHIA, July 23, 2025 /PRNewswire/ -- Home Genius Exteriors (HGE) donated and installed...
Boca Raton, FL, July 23, 2025 (GLOBE NEWSWIRE) -- Hydrasphere Plus, a Florida-based skincare innovator, has officially launched a pioneering three-pillar system designed to transform the science of facial health. Built on decades of dermatological research and cosmetic formulation expertise, the new Hydrasphere Plus system uniquely targets skin texture, facial muscle tone, and collagen production—three biological pillars essential to long-term skin vitality.
SASKATOON, SK, July 23, 2025 /CNW/ - Upcycle Minerals Inc. ("Upcycle" or the "Company") (Private) announces the official kickoff of its Brine to Potassium...
ASX Release
$132M Treasury Build in Q4 FY25
PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited (ASX | TSX: WGX - Westgold or the Company) is pleased to report results...
Franchise Expansion, New Hires, and a New Offering Mark Another Milestone Quarter for the Home Services Leader
CHARLOTTESVILLE, Va., July 22, 2025 /PRNewswire/ -- Premium...
New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.
The Japan in vitro diagnostics market, valued at USD 3.97 Billion in 2024, is projected to grow at a CAGR of 6.20%, reaching USD 7.24 Billion by 2034. Key growth drivers include an aging population, demand for personalized medicine, AI-integrated testing, and home-based diagnostics. Strategic partnerships and regulatory approvals boost market potential.
The Japan in vitro diagnostics market, valued at USD 3.97 Billion in 2024, is projected to grow at a CAGR of 6.20%, reaching USD 7.24 Billion by 2034. Key growth drivers include an aging population, demand for personalized medicine, AI-integrated testing, and home-based diagnostics. Strategic partnerships and regulatory approvals boost market potential.
STOCKHOLM, July 22, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including...
Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...